Abstract: A humanized antibody or a functional fragment thereof binding to a human-derived Eval protein, an antibody-drug conjugate comprising the humanized antibody or a functional fragment thereof, or a chimeric antigen receptor comprising an antibody or a functional fragment thereof binding to a human-derived Eval protein.
Type:
Application
Filed:
September 28, 2022
Publication date:
June 12, 2025
Applicants:
CURED INC., NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM
Abstract: For the object of establishing means for treating chronic kidney diseases including Alport syndrome, the present invention provides a pharmaceutical composition comprising a) a renin-angiotensin-system inhibitor and b) at least one type of an omega-3 polyunsaturated fatty acid, an ester thereof, a metabolite thereof, a pharmaceutically acceptable salt thereof, or a triglyceride thereof.
Abstract: The present invention provides a component having effects in vivo of improving or optimizing the intestinal environment, suppressing intestinal putrefaction, or suppressing alternation of intestinal bacterial growth and/or pathological changes of intestinal bacterial growth in gut microbiota. The invention also provides an active ingredient suitably used for treating intestinal diseases. The invention provides a monoclonal IgA antibody that binds to amino acids 11 to 333 of serine hydroxymethyltransferase.
© 2026 Justia
